Samarth Kulkarni
Showing 1–2 of 2 transcripts.
- Milken Institute1h 1m
Where Is the Next Cure? | Global Conference 2024
Alice Park, Noubar Afeyan, Aloe Blacc, Daphne Koller, Samarth Kulkarni, Pablo Legorreta
Leading biotech executives and researchers are redefining the industry by shifting from chronic small-molecule management to precise, curative systems-based therapies like CRISPR and mRNA platforms. This transition, fueled by artificial intelligence and a "reverse translation" innovation model, has accelerated clinical timelines while projecting a $100 billion market for GLP-1 drugs and new organ-editing solutions. Despite regulatory hurdles and high initial costs for treatments like sickle cell gene editing, stakeholders anticipate that maturing technologies and scalable manufacturing will eventually democratize access to these transformative medical breakthroughs.
- Goldman Sachs29 min
Samarth Kulkarni, CEO, CRISPR Therapeutics
Samarth Kulkarni, Dr. Sam Kulkarni
Dr. Sam Kulkarni of CRISPR Therapeutics outlines a pivotal industry shift where the convergence of delivery systems and genome-editing technology enables a transition from chronic symptom management to one-time curative procedures for rare and common diseases. By leveraging a highly specific RNA passcode to mitigate off-target risks, the company is advancing both ex vivo and in vivo therapies, successfully treating blood disorders while expanding into metabolic conditions and sustainable agriculture. This strategic execution has allowed CRISPR Therapeutics to raise $3.5 billion and maintain an aggressive R&D focus despite a broader biotech market correction, positioning the firm to deliver the first wave of permanent genetic cures within the next decade.